Merck and Co., Inc. (MRK) |
| 115.87 2.87 (2.54%) 05-21 16:00 |
| Open: | 113.34 |
| High: | 115.98 |
| Low: | 112.09 |
| Volume: | 4,795,965 |
| Market Cap: | 286,179(M) |
| PE Ratio: | 32.64 |
| Exchange: | New York Stock Exchange |
| Industry: | Drug Manufacturers - General |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 139.41 |
| Resistance 1: | 119.36 |
| Pivot price: | 112.88 |
| Support 1: | 112.28 |
| Support 2: | 107.90 |
| 52w High: | 125.14 |
| 52w Low: | 75.4 |
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
| EPS | 3.550 |
| Book Value | 18.580 |
| PEG Ratio | 5.27 |
| Gross Profit | 20.429 |
| Profit Margin (%) | 13.59 |
| Operating Margin (%) | 38.60 |
| Return on Assets (ttm) | 12.6 |
| Return on Equity (ttm) | 18.9 |
Thu, 21 May 2026
2 Reasons to Watch MRK and 1 to Stay Cautious - Yahoo Finance
Thu, 21 May 2026
Eli Lilly vs. Merck: Which Pharma Stock Looks Stronger Now? - TradingView
Wed, 20 May 2026
Cullen Frost Bankers Inc. Has $22.74 Million Position in Merck & Co., Inc. $MRK - MarketBeat
Tue, 19 May 2026
HighTower Advisors LLC Sells 50,990 Shares of Merck & Co., Inc. $MRK - MarketBeat
Mon, 18 May 2026
Merck & Co., Inc. Trade Ideas — LSX:A0YD8Q - TradingView
Mon, 18 May 2026
Merck's drug helps uterine cancer patients live longer in late-stage trial - Reuters
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |